Antibody-Mediated Therapy and Other Emerging Therapies in Cancer Treatment

Topic Information

Dear Colleagues,

Recent advances in antibody-mediated therapy have significantly improved its therapeutic efficacy in many types of cancer. Antibody-mediated therapy includes the following:

1. Monoclonal antibodies against specific targets associated with cancer cell survival, progression, metastasis, and drug resistance;
2. Monoclonal antibodies against specific targets that are relatively highly expressed in cancer cells or are cancer-specific, regardless of cancer cell survival progression, metastasis, or drug resistance;
3. Monoclonal antibodies against specific targets in cancer cells or normal cells that modulate the tumor microenvironment, especially immune systems;
4. Antibody–drug conjugates (ADCs) are complex molecules consisting of antibodies conjugated to biologically active cancer cell-killing substances.

These antibody-mediated therapies have been widely used as combination therapies due to their synergistic effects with cytotoxic anticancer drugs. Eventually, ADCs, complex molecules consisting of antibodies and cytotoxic substances, were developed to improve treatment outcomes. However, the side effects of ADCs are very serious, requiring careful monitoring during treatment. Therefore, this Topic was prepared to deeply examine the efficacy, related mechanisms, and toxicities of the latest antibody-related therapies or other novel therapies for each cancer.

Scope of the Topic

1. Monoclonal antibodies as monotherapy, as antibody–drug conjugates (ADCs), or in combination with other drugs in cancer treatment:
2. Efficacy, mechanism of action, and treatment guidelines;
3. Predictive/prognostic biomarkers;
4. Toxicity and management.
5. Other emerging therapies in cancer treatment (CAR-T cell therapy, NK or other cell therapies, oncolytic virus therapy, cancer vaccines, targeted therapy, etc.). 

Dr. Won Sup Lee
Prof. Dr. Yaewon Yang
Prof. Dr. Seil Go
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Cancers cancers	4.4	8.8	2009	20.3 Days	CHF 2900	Submit
Current Issues in Molecular Biology cimb	3.0	3.7	1999	17.8 Days	CHF 2200	Submit
Current Oncology curroncol	3.4	4.9	1994	21.5 Days	CHF 2200	Submit
Scientia Pharmaceutica scipharm	2.5	4.6	1930	38.1 Days	CHF 1000	Submit
Antibodies antibodies	2.7	4.5	2012	22.2 Days	CHF 1800	Submit
International Journal of Molecular Sciences ijms	4.9	9.0	2000	20.5 Days	CHF 2900	Submit
International Journal of Translational Medicine ijtm	-	2.2	2021	25.9 Days	CHF 1000	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Cancers CIMB Current Oncology Sci. Pharm. Antibodies IJMS IJTM

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

attachment

Supplementary material:
Supplementary File 1 (ZIP, 3914 KB)

17 pages, 1957 KB  

Open AccessArticle

In Silico Multitarget Profiling of Non-Selective Beta-Blockers Highlights Their Potential as Key Agents in Breast Cancer Adjuvant Therapy via ADRB2, ERBB2, and NPYR Receptors

by Felipe Muñoz-González, José Correa-Basurto, Iván Ignacio-Mejia and Cindy Bandala

Curr. Issues Mol. Biol. 2025, 47(10), 789; https://doi.org/10.3390/cimb47100789 - 23 Sep 2025

Viewed by 110

Abstract

Breast cancer (BC) is associated with multiple molecular factors such as overexpression of the beta-2 adrenergic receptor (ADRB2) and the overproduction of its agonists (norepinephrine and epinephrine). The role of adrenergic signaling in BC highlights the therapeutic potential of non-selective beta-blockers (nsBBs) as [...] Read more.

Breast cancer (BC) is associated with multiple molecular factors such as overexpression of the beta-2 adrenergic receptor (ADRB2) and the overproduction of its agonists (norepinephrine and epinephrine). The role of adrenergic signaling in BC highlights the therapeutic potential of non-selective beta-blockers (nsBBs) as inhibitors of well-established protumor signaling pathways related to ADRB2 and their possible affinity for other important protumoral receptors. Our aim was to identify how nsBBs currently prescribed may also interact with receptors other than ADRB2, which are related to the pathophysiology of BC, using bioinformatic intracellular pathway analysis (BIPA). Subsequently, the affinity of nsBBs for both ADRB2 and the targets identified by BIPA was evaluated. We found that, beyond ADRB2, both receptor tyrosine kinase 2 (ERBB2) and neuropeptide Y receptor (NPYR) are promising targets for nsBBs in the adjuvant treatment of BC, according to BIPA. Docking studies showed that the nsBB with the highest binding affinity (ΔG) was carvedilol (−10.5 kcal/mol), followed by propranolol (−8.5 kcal/mol). These in silico findings suggest previously unrecognized pharmacological mechanisms for nsBBs in the possible treatment for BC. Notably, differences in receptor affinity were observed among the nsBBs, with carvedilol exhibiting the strongest binding affinity values on ADRB2, ERBB2, and NPYR as biological targets against BC cells. These promising results require future experimental validation. Full article

(This article belongs to the Topic Antibody-Mediated Therapy and Other Emerging Therapies in Cancer Treatment)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-1